Amended Statement of Beneficial Ownership (3/a)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Vexler Vladimir

2. Date of Event Requiring Statement (MM/DD/YYYY) 11/16/2018

3. Issuer Name and Ticker or Trading Symbol

Coherus BioSciences, Inc. [CHRS]

(Last) (First) (Middle)

COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___ X ___ Officer (give title below) _____ Other (specify below)
Chief Scientific Officer /

(Street)

REDWOOD CITY, CA 94065

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

11/20/2018

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, $0.0001 par value	7828 ⁽¹⁾	D

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽²⁾	2/28/2023	Common Stock	71982	$2.0838	D
Stock Option (right to buy)	⁽³⁾	4/1/2025	Common Stock	25000	$29.00	D
Stock Option (right to buy)	⁽⁴⁾	2/26/2026	Common Stock	25000	$14.43	D
Stock Option (right to buy)	⁽⁵⁾	5/11/2026	Common Stock	24618	$17.17	D
Stock Option (right to buy)	⁽⁶⁾	4/3/2027	Common Stock	25000	$20.15	D
Stock Option (right to buy)	⁽⁷⁾	8/6/2027	Common Stock	50000	$12.70	D
Stock Option (right to buy)	⁽⁸⁾	11/15/2027	Common Stock	25000	$9.30	D
Stock Option (right to buy)	⁽⁹⁾	2/1/2028	Common Stock	75000	$10.05	D

Explanation of Responses:
(1)	This Form 3 amendment has been filed solely to correct the amount of securities beneficially owned as shown in Table I, column 2 of both the original Form 3 and the Form 3A.
(2)	The original grant was for 86,982 shares, of which 15,000 shares have been exercised and sold. The remaining shares underlying this option are fully vested and exercisable as of the date hereof.
(3)	A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from April 1, 2015, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
(4)	A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from March 1, 2016, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
(5)	A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from May 6, 2016, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
(6)	A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from April 3, 2017, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
(7)	A portion of the shares underlying this option are vested and exercisable as of the date hereof. The underlying shares subject to the option vest and become exercisable over two years as follows: Fifty percent (50%) of the underlying shares subject to the option vest and become exercisable on August 1, 2018, an additional twenty-five percent (25%) of the underlying shares subject to the option vest and become exercisable on February 1, 2019 and twenty-five percent (25%) of the underlying shares subject to the option vest and become exercisable on August 1, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
(8)	A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from November 15, 2017, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
(9)	A portion of the shares underlying this option are vested and exercisable as of the date hereof. The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Vexler Vladimir COHERUS BIOSCIENCES, INC. 333 TWIN DOLPHIN DRIVE, SUITE 600 REDWOOD CITY, CA 94065			Chief Scientific Officer

Signatures
/s/ Jean Frederic Viret, as Attorney-in-Fact for Vladimir Vexler		1/15/2019
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.